{"success":true,"data":{"pressRelease":{"id":"177343","rtpr_id":"nPn6kJNcSa-20261022","ticker":"ARDX","exchange":"NASDAQ","all_tickers":["ARDX"],"title":"ARDX Shareholder Alert: November 16, 2026 Lead Plaintiff Deadline in Ardelyx, Inc. Securities Class Action - Contact SueWallSt","author":"PR Newswire","published_at":"2026-10-22T14:11:03.627Z","article_body":"ARDX Shareholder Alert: November 16, 2026 Lead Plaintiff Deadline in Ardelyx, Inc. Securities Class Action - Contact SueWallSt\nPR Newswire\n\nNEW YORK, Oct. 22, 2026\n\nRegulatory Compliance Focus: The lawsuit contends Ardelyx assured the market\nit had confidently addressed a shifting Medicare reimbursement environment for\nXPHOZAH and IBSRELA, while payer utilization-management requirements were\nallegedly tightening behind the scenes.\n\nNEW YORK, Oct. 22, 2026 /PRNewswire/ -- SueWallSt notifies investors in\nArdelyx, Inc. (NASDAQ: ARDX) that a securities class action has been filed on\nbehalf of shareholders who purchased or otherwise acquired ARDX securities\nbetween January 13, 2025 and August 6, 2026. Submit your information now\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4803455-17&h=1313400003&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fardelyx-inc-class-action-lawsuit-ardx%3Fprid%3D207689%26wire%3D4&a=Submit+your+information+now)\n. You may also contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com)  or (888) SueWallSt.\n\nARDX closed at $4.87 on August 6, 2026 and closed at $4.00 the next session, a\none-day decline of $0.87 per share, or approximately 18%. The lead plaintiff\ndeadline is November 16, 2026.\n\nWhat the Company Disclosed About Medicare Coverage Changes\n\nAfter XPHOZAH lost Medicare Part D coverage, Ardelyx's public disclosure\nlanguage indicated that the only thing that had changed was payer coverage and\nthat prescribing and patient access would continue as before. Company\nstatements in February 2025 described the reimbursement environment as a\nchallenge management had confidently addressed, while reaffirming combined\npeak sales expectations of $1.75 billion for XPHOZAH and IBSRELA.\n\nThe complaint challenges whether that framing told investors what they needed\nto know about the regulatory and payer forces already shaping demand.\n\nDisclosure Gaps Alleged\n\n * Alleged failure to disclose that prior authorization requirements had become\nmore stringent even as the Company described its access strategy as working\n * Alleged omission that payer step edit requirements were slowing new-patient\nstarts and delaying prescription fulfillment\n * Alleged reaffirmation of full year 2025 IBSRELA guidance of $240 million to\n$250 million without disclosing intensifying utilization-management pressure\n * Alleged presentation of the Medicare Part D exclusion as a coverage change the\nCompany's patient services program could absorb\n * Alleged reliance on general reimbursement-environment commentary in place of\nspecific disclosure of access barriers said to be building\n * Alleged maintenance of a $750 million long-term XPHOZAH target and a greater\nthan $1 billion IBSRELA target while those barriers allegedly persisted\n\"General commentary about a challenging reimbursement environment is not the\nsame as disclosing that payer utilization-management requirements are already\nslowing new-patient starts. The complaint alleges Ardelyx reaffirmed a $750\nmillion peak sales target for XPHOZAH well after Medicare Part D coverage\nended, and shareholders are entitled to ask what was known at the time.\" --\nJoseph E. Levi, Esq.\n\nRegulatory Reality Behind the August 6, 2026 Guidance Reset\n\nAfter the market closed on August 6, 2026, Ardelyx announced a reduction in\nfull year 2026 IBSRELA revenue guidance and withdrew its long-term XPHOZAH\nrevenue guidance. The Company attributed the reduction to significantly\nincreased payer utilization-management processes that restricted patient\naccess and slowed new-patient starts, and cited evolving market dynamics and\nuncertainty regarding future XPHOZAH growth. The action, brought in the United\nStates District Court for the District of Massachusetts, asserts claims under\nSections 10(b) and 20(a) of the Securities Exchange Act and Rule 10b-5.\n\nFind out if you might qualify to recover losses\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4803455-17&h=1739535315&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fardelyx-inc-class-action-lawsuit-ardx%3Fprid%3D207689%26wire%3D4&a=Find+out+if+you+might+qualify+to+recover+losses)\n or call (888) SueWallSt.\n\nWHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi &\nKorsinsky LLP has established itself as a nationally-recognized securities\nlitigation firm that has secured hundreds of millions of dollars for aggrieved\nshareholders and built a track record of winning high-stakes cases. The firm\nhas extensive expertise representing investors in complex securities\nlitigation and a team of over 70 employees to serve our clients. For seven\nyears in a row, Levi & Korsinsky has ranked in ISS Securities Class Action\nServices' Top 50 Report as one of the top securities litigation firms in the\nUnited States.\n\nFrequently Asked Questions About the ARDX Lawsuit\n\nQ: What is the ARDX class action lawsuit about? A: A securities class action\nhas been filed against Ardelyx, Inc. (NASDAQ: ARDX) alleging materially false\nand misleading statements between January 13, 2025 and August 6, 2026. Shares\nfell approximately 18% after the Company disclosed a reduction in full year\n2026 IBSRELA revenue guidance and the withdrawal of its long-term XPHOZAH\nrevenue guidance, citing significantly increased payer utilization-management\nprocesses. Investors who purchased shares during the Class Period and suffered\nlosses may be eligible to seek compensation.\n\nQ: Who is eligible to join the ARDX investor lawsuit? A: Investors who\npurchased ARDX stock or securities between January 13, 2025 and August 6, 2026\nand suffered financial losses may be eligible. Eligibility is based on\npurchase date and documented losses, not on whether you still hold the shares.\n\nQ: What court was the ARDX class action filed in? A: The case was filed in\nthe United States District Court for the District of Massachusetts, governed\nby the Private Securities Litigation Reform Act of 1995.\n\nQ: What do ARDX investors need to do right now? A: Investors may gather\nbrokerage records showing purchase dates, share quantities, and prices paid.\nSubmit your information for a no-cost, no-obligation evaluation of your\npotential recovery\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4803455-17&h=1960828161&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fardelyx-inc-class-action-lawsuit-ardx%3Fprid%3D207689%26wire%3D4&a=Submit+your+information+for+a+no-cost%2C+no-obligation+evaluation+of+your+potential+recovery)\n. No immediate action is required to remain eligible as an absent class\nmember.\n\nQ: What is a lead plaintiff and why does it matter? A: A lead plaintiff is\nthe investor appointed by the court to represent the entire class. Lead\nplaintiffs are typically investors with the largest documented losses. Being\nappointed does not increase individual recovery but gives direct oversight of\nhow the case is run.\n\nQ: What if I already sold my ARDX shares, can I still recover losses? A: Yes.\nEligibility is based on when you purchased, not whether you still hold the\nshares. Investors who bought during the Class Period and sold at a loss may\nstill be eligible to participate.\n\nQ: What does it cost me to participate? A: There is no upfront cost to submit\nyour information and review whether you may be eligible to recover. Should you\nchoose to participate in the securities class action, they are generally\nhandled on a contingency basis, with any attorneys' fees and expenses subject\nto court approval.\n\nQ: What if I live outside the United States? A: U.S. securities class actions\ngenerally cover purchases on U.S. exchanges regardless of the investor's\ncountry of residence.\n\nCONTACT:\n\nLevi & Korsinsky, LLP\n\nJoseph E. Levi, Esq.\n\n33 Whitehall Street, 27th Floor\n\nNew York, NY 10004\n\njlevi@SueWallSt.com (mailto:jlevi@SueWallSt.com)\n\nTel: (888) SueWallSt\n\nFax: (212) 363-7171\n\nAttorney Advertising. Prior results do not guarantee similar outcomes.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/ardx-shareholder-alert-november-16-2026-lead-plaintiff-deadline-in-ardelyx-inc-securities-class-action---contact-suewallst-302916575.html\n(https://www.prnewswire.com/news-releases/ardx-shareholder-alert-november-16-2026-lead-plaintiff-deadline-in-ardelyx-inc-securities-class-action---contact-suewallst-302916575.html)\n\nSOURCE SueWallSt.com\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1812443/suewallst-logo-1-Logo.jpg?id=OA3032513\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn6kJNcSa-20261022","title":"ARDX Shareholder Alert: November 16, 2026 Lead Plaintiff Deadline in Ardelyx, Inc. Securities Class Action - Contact SueWallSt","author":"PR Newswire","ticker":"ARDX","created":"2026-10-22T14:11:03.627Z","tickers":["ARDX"],"exchange":"NASDAQ","article_body":"ARDX Shareholder Alert: November 16, 2026 Lead Plaintiff Deadline in Ardelyx, Inc. Securities Class Action - Contact SueWallSt\nPR Newswire\n\nNEW YORK, Oct. 22, 2026\n\nRegulatory Compliance Focus: The lawsuit contends Ardelyx assured the market\nit had confidently addressed a shifting Medicare reimbursement environment for\nXPHOZAH and IBSRELA, while payer utilization-management requirements were\nallegedly tightening behind the scenes.\n\nNEW YORK, Oct. 22, 2026 /PRNewswire/ -- SueWallSt notifies investors in\nArdelyx, Inc. (NASDAQ: ARDX) that a securities class action has been filed on\nbehalf of shareholders who purchased or otherwise acquired ARDX securities\nbetween January 13, 2025 and August 6, 2026. Submit your information now\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4803455-17&h=1313400003&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fardelyx-inc-class-action-lawsuit-ardx%3Fprid%3D207689%26wire%3D4&a=Submit+your+information+now)\n. You may also contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com)  or (888) SueWallSt.\n\nARDX closed at $4.87 on August 6, 2026 and closed at $4.00 the next session, a\none-day decline of $0.87 per share, or approximately 18%. The lead plaintiff\ndeadline is November 16, 2026.\n\nWhat the Company Disclosed About Medicare Coverage Changes\n\nAfter XPHOZAH lost Medicare Part D coverage, Ardelyx's public disclosure\nlanguage indicated that the only thing that had changed was payer coverage and\nthat prescribing and patient access would continue as before. Company\nstatements in February 2025 described the reimbursement environment as a\nchallenge management had confidently addressed, while reaffirming combined\npeak sales expectations of $1.75 billion for XPHOZAH and IBSRELA.\n\nThe complaint challenges whether that framing told investors what they needed\nto know about the regulatory and payer forces already shaping demand.\n\nDisclosure Gaps Alleged\n\n * Alleged failure to disclose that prior authorization requirements had become\nmore stringent even as the Company described its access strategy as working\n * Alleged omission that payer step edit requirements were slowing new-patient\nstarts and delaying prescription fulfillment\n * Alleged reaffirmation of full year 2025 IBSRELA guidance of $240 million to\n$250 million without disclosing intensifying utilization-management pressure\n * Alleged presentation of the Medicare Part D exclusion as a coverage change the\nCompany's patient services program could absorb\n * Alleged reliance on general reimbursement-environment commentary in place of\nspecific disclosure of access barriers said to be building\n * Alleged maintenance of a $750 million long-term XPHOZAH target and a greater\nthan $1 billion IBSRELA target while those barriers allegedly persisted\n\"General commentary about a challenging reimbursement environment is not the\nsame as disclosing that payer utilization-management requirements are already\nslowing new-patient starts. The complaint alleges Ardelyx reaffirmed a $750\nmillion peak sales target for XPHOZAH well after Medicare Part D coverage\nended, and shareholders are entitled to ask what was known at the time.\" --\nJoseph E. Levi, Esq.\n\nRegulatory Reality Behind the August 6, 2026 Guidance Reset\n\nAfter the market closed on August 6, 2026, Ardelyx announced a reduction in\nfull year 2026 IBSRELA revenue guidance and withdrew its long-term XPHOZAH\nrevenue guidance. The Company attributed the reduction to significantly\nincreased payer utilization-management processes that restricted patient\naccess and slowed new-patient starts, and cited evolving market dynamics and\nuncertainty regarding future XPHOZAH growth. The action, brought in the United\nStates District Court for the District of Massachusetts, asserts claims under\nSections 10(b) and 20(a) of the Securities Exchange Act and Rule 10b-5.\n\nFind out if you might qualify to recover losses\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4803455-17&h=1739535315&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fardelyx-inc-class-action-lawsuit-ardx%3Fprid%3D207689%26wire%3D4&a=Find+out+if+you+might+qualify+to+recover+losses)\n or call (888) SueWallSt.\n\nWHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi &\nKorsinsky LLP has established itself as a nationally-recognized securities\nlitigation firm that has secured hundreds of millions of dollars for aggrieved\nshareholders and built a track record of winning high-stakes cases. The firm\nhas extensive expertise representing investors in complex securities\nlitigation and a team of over 70 employees to serve our clients. For seven\nyears in a row, Levi & Korsinsky has ranked in ISS Securities Class Action\nServices' Top 50 Report as one of the top securities litigation firms in the\nUnited States.\n\nFrequently Asked Questions About the ARDX Lawsuit\n\nQ: What is the ARDX class action lawsuit about? A: A securities class action\nhas been filed against Ardelyx, Inc. (NASDAQ: ARDX) alleging materially false\nand misleading statements between January 13, 2025 and August 6, 2026. Shares\nfell approximately 18% after the Company disclosed a reduction in full year\n2026 IBSRELA revenue guidance and the withdrawal of its long-term XPHOZAH\nrevenue guidance, citing significantly increased payer utilization-management\nprocesses. Investors who purchased shares during the Class Period and suffered\nlosses may be eligible to seek compensation.\n\nQ: Who is eligible to join the ARDX investor lawsuit? A: Investors who\npurchased ARDX stock or securities between January 13, 2025 and August 6, 2026\nand suffered financial losses may be eligible. Eligibility is based on\npurchase date and documented losses, not on whether you still hold the shares.\n\nQ: What court was the ARDX class action filed in? A: The case was filed in\nthe United States District Court for the District of Massachusetts, governed\nby the Private Securities Litigation Reform Act of 1995.\n\nQ: What do ARDX investors need to do right now? A: Investors may gather\nbrokerage records showing purchase dates, share quantities, and prices paid.\nSubmit your information for a no-cost, no-obligation evaluation of your\npotential recovery\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4803455-17&h=1960828161&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fardelyx-inc-class-action-lawsuit-ardx%3Fprid%3D207689%26wire%3D4&a=Submit+your+information+for+a+no-cost%2C+no-obligation+evaluation+of+your+potential+recovery)\n. No immediate action is required to remain eligible as an absent class\nmember.\n\nQ: What is a lead plaintiff and why does it matter? A: A lead plaintiff is\nthe investor appointed by the court to represent the entire class. Lead\nplaintiffs are typically investors with the largest documented losses. Being\nappointed does not increase individual recovery but gives direct oversight of\nhow the case is run.\n\nQ: What if I already sold my ARDX shares, can I still recover losses? A: Yes.\nEligibility is based on when you purchased, not whether you still hold the\nshares. Investors who bought during the Class Period and sold at a loss may\nstill be eligible to participate.\n\nQ: What does it cost me to participate? A: There is no upfront cost to submit\nyour information and review whether you may be eligible to recover. Should you\nchoose to participate in the securities class action, they are generally\nhandled on a contingency basis, with any attorneys' fees and expenses subject\nto court approval.\n\nQ: What if I live outside the United States? A: U.S. securities class actions\ngenerally cover purchases on U.S. exchanges regardless of the investor's\ncountry of residence.\n\nCONTACT:\n\nLevi & Korsinsky, LLP\n\nJoseph E. Levi, Esq.\n\n33 Whitehall Street, 27th Floor\n\nNew York, NY 10004\n\njlevi@SueWallSt.com (mailto:jlevi@SueWallSt.com)\n\nTel: (888) SueWallSt\n\nFax: (212) 363-7171\n\nAttorney Advertising. Prior results do not guarantee similar outcomes.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/ardx-shareholder-alert-november-16-2026-lead-plaintiff-deadline-in-ardelyx-inc-securities-class-action---contact-suewallst-302916575.html\n(https://www.prnewswire.com/news-releases/ardx-shareholder-alert-november-16-2026-lead-plaintiff-deadline-in-ardelyx-inc-securities-class-action---contact-suewallst-302916575.html)\n\nSOURCE SueWallSt.com\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1812443/suewallst-logo-1-Logo.jpg?id=OA3032513\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-22T14:11:03.681975335Z","server_sent_at_ms":1792678263681},"received_at":"2026-10-22T14:11:03.740Z","source_url":"https://www.prnewswire.com/news-releases/ardx-shareholder-alert-november-16-2026-lead-plaintiff-deadline-in-ardelyx-inc-securities-class-action---contact-suewallst-302916575.html"},"analysis":{"id":"165291","press_release_id":"177343","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":["underlying securities class action alleges disclosure gaps around Medicare Part D exclusion and payer utilization-management pressure","ARDX dropped ~18% after the August 6, 2026 guidance cut and XPHOZAH guidance withdrawal"],"eventType":"legal_litigation","narrative":"SueWallSt, powered by Levi & Korsinsky, issued a shareholder alert publicizing a securities class action against Ardelyx with a November 16, 2026 lead plaintiff deadline.\n\nThe complaint covers purchasers of ARDX between January 13, 2025 and August 6, 2026 and alleges misleading statements about Medicare reimbursement and payer utilization-management pressure on XPHOZAH and IBSRELA.\n\nARDX fell about 18% on August 7, 2026 after the company cut 2026 IBSRELA guidance and withdrew long-term XPHOZAH guidance. This release is law-firm solicitation, not new issuer disclosure.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{"customDimensions":{"stock_drop":"$4.87 to $4.00 on Aug 7, 2026 (~18%)","class_period":"January 13, 2025 - August 6, 2026","lead_plaintiff_deadline":"November 16, 2026"}},"quotedText":"General commentary about a challenging reimbursement environment is not the same as disclosing that payer utilization-management requirements are already slowing new-patient starts.","namedEntities":{"people":[{"name":"Joseph E. Levi, Esq.","role":"attorney, Levi & Korsinsky LLP"}],"products":["XPHOZAH","IBSRELA"],"companies":[{"name":"Ardelyx, Inc.","ticker":"ARDX","relationship":"issuer/target of class action"},{"name":"Levi & Korsinsky LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$1.75 billion","context":"allegedly reaffirmed combined peak sales expectation for XPHOZAH and IBSRELA"},{"amount":"$240 million to $250 million","context":"allegedly reaffirmed FY2025 IBSRELA guidance"},{"amount":"$750 million","context":"long-term XPHOZAH peak sales target allegedly maintained"},{"amount":"$4.87","context":"ARDX close on August 6, 2026"},{"amount":"$4.00","context":"ARDX close on August 7, 2026"},{"amount":"$0.87","context":"one-day per-share decline"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation issued by SueWallSt/Levi & Korsinsky publicizing a previously filed securities class action and lead plaintiff deadline. No certified class, no settlement, no new issuer disclosure."},"tickerRelevance":{"others":[],"primary":"ARDX"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingEventNote":"guidance reset already public; this release adds no new issuer information"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"SueWallSt, powered by Levi & Korsinsky, issued a shareholder alert publicizing a securities class action against Ardelyx with a November 16, 2026 lead plaintiff deadline.\n\nThe complaint covers purchasers of ARDX between January 13, 2025 and August 6, 2026 and alleges misleading statements about Medicare reimbursement and payer utilization-management pressure on XPHOZAH and IBSRELA.\n\nARDX fell about 18% on August 7, 2026 after the company cut 2026 IBSRELA guidance and withdrew long-term XPHOZAH guidance. This release is law-firm solicitation, not new issuer disclosure.","key_figures":{"customDimensions":{"stock_drop":"$4.87 to $4.00 on Aug 7, 2026 (~18%)","class_period":"January 13, 2025 - August 6, 2026","lead_plaintiff_deadline":"November 16, 2026"}},"named_entities":{"people":[{"name":"Joseph E. Levi, Esq.","role":"attorney, Levi & Korsinsky LLP"}],"products":["XPHOZAH","IBSRELA"],"companies":[{"name":"Ardelyx, Inc.","ticker":"ARDX","relationship":"issuer/target of class action"},{"name":"Levi & Korsinsky LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$1.75 billion","context":"allegedly reaffirmed combined peak sales expectation for XPHOZAH and IBSRELA"},{"amount":"$240 million to $250 million","context":"allegedly reaffirmed FY2025 IBSRELA guidance"},{"amount":"$750 million","context":"long-term XPHOZAH peak sales target allegedly maintained"},{"amount":"$4.87","context":"ARDX close on August 6, 2026"},{"amount":"$4.00","context":"ARDX close on August 7, 2026"},{"amount":"$0.87","context":"one-day per-share decline"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-22T14:11:09.777Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingEventNote":"guidance reset already public; this release adds no new issuer information"}},"durationMs":6002,"modelName":"glm-5.3-flashx"}}